ZEPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zepp Health Corp (ZEPP) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown significant revenue growth, the financial performance is weak with declining net income, EPS, and gross margin. Technical indicators and trading trends are neutral, and there are no strong positive catalysts or proprietary trading signals to support immediate action.
The MACD is positive at 0.549 but contracting, RSI is neutral at 53.189, and moving averages are converging, indicating no strong directional trend. Key support and resistance levels are at S1: 18.129 and R1: 25.904, with the current price at 22.5 sitting in between these levels.
The launch of the Amazfit T-Rex Ultra 2 smartwatch with advanced features could drive consumer interest and sales in the short term.
Weak financial performance in the latest quarter, including a significant drop in net income (-87.80% YoY) and EPS (-80.00% YoY). Gross margin also declined by 6.03%. No significant trading trends from hedge funds or insiders.
In Q3 2025, revenue increased by 78.49% YoY to $75,789,000. However, net income dropped to -$1,616,000 (-87.80% YoY), EPS fell to -0.01 (-80.00% YoY), and gross margin declined to 38.16% (-6.03% YoY).
No data on analyst ratings or price target changes is available.
